|
1
|
Huang R, Wang K, Gao L and Gao W: TIMP1 is
a potential key gene associated with the pathogenesis and prognosis
of ulcerative colitis-associated colorectal cancer. OncoTargets
Ther. 12:8895–8904. 2019. View Article : Google Scholar
|
|
2
|
Kawachi H: Histopathological diagnosis of
ulcerative colitis-associated neoplasia. Dig Endosc. 1 (Suppl
31):31–35. 2019. View Article : Google Scholar
|
|
3
|
Riddell RH, Goldman H, Ransohoff DF,
Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton
SR, Morson BC, et al: Dysplasia in inflammatory bowel disease:
Standardized classification with provisional clinical applications.
Hum Pathol. 14:931–968. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ungaro R, Mehandru S, Allen PB,
Peyrin-Biroulet L and Colombel JF: Ulcerative colitis. Lancet.
389:1756–1770. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kozomara A and Griffiths-Jones S: miRBase:
Integrating microRNA annotation and deep-sequencing data. Nucleic
Acids Res. 39:D152–D157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koukos G, Polytarchou C, Kaplan JL,
Morley-Fletcher A, Gras-Miralles B, Kokkotou E, Baril-Dore M,
Pothoulakis C, Winter HS and Iliopoulos D: MicroRNA-124 regulates
STAT3 expression and is down-regulated in colon tissues of
pediatric patients with ulcerative colitis. Gastroenterology.
145:842–852.e842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gwiggner M, Martinez-Nunez RT, Whiteoak
SR, Bondanese VP, Claridge A, Collins JE, Cummings JRF and
Sanchez-Elsner T: MicroRNA-31 and MicroRNA-155 are overexpressed in
ulcerative colitis and regulate IL-13 signaling by targeting
interleukin 13 receptor α-1. Genes (Basel). 9:852018. View Article : Google Scholar
|
|
8
|
Zhang XF, Tu R, Li K, Ye P and Cui X:
Tumor suppressor PTPRJ is a target of miR-155 in colorectal cancer.
J Cell Biochem. 118:3391–3400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Haidari A, Algaber A, Madhi R, Syk I
and Thorlacius H: miR-155-5p controls colon cancer cell migration
via post-transcriptional regulation of human antigen R (HuR).
Cancer Lett. 421:145–151. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
The Gene Ontology Consortium: Expansion of
the gene ontology knowledgebase and resources. Nucleic Acids Res.
45:D331–D338. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res. 45:D353–D361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pekow J, Meckel K, Dougherty U, Huang Y,
Chen X, Almoghrabi A, Mustafi R, Ayaloglu-Butun F, Deng Z, Haider
HI, et al: miR-193a-3p is a key tumor suppressor in ulcerative
colitis-associated colon cancer and promotes carcinogenesis through
upregulation of IL17RD. Clin Cancer Res. 23:5281–5291. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gutierrez-Uribe JA, Salinas-Santander M,
Serna-Guerrero D, Serna-Saldivar SRO, Rivas-Estilla AM and
Rios-Ibarra CP: Inhibition of miR31 and miR92a as oncological
biomarkers in RKO colon cancer cells treated with
kaempferol-3-O-glycoside isolated from black bean. J Med Food.
23:50–55. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li T, Luo W, Liu K, Lv X and Xi T: miR-31
promotes proliferation of colon cancer cells by targeting E2F2.
Biotechnol Lett. 37:523–532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie ZY, Wang FF, Xiao ZH, Liu SF, Tang SL
and Lai YL: Overexpressing microRNA-34a overcomes ABCG2-mediated
drug resistance to 5-FU in side population cells from colon cancer
via suppressing DLL1. J Biochem. 167:557–564. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li X, Li C, Li D, Yang L, Jin J and Zhang
B: lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in
colon cancer by targeting the miR-34a/ATG4B pathway. OncoTargets
Ther. 12:2649–2660. 2019. View Article : Google Scholar
|
|
21
|
Zhuang M, Zhao S, Jiang Z, Wang S, Sun P,
Quan J, Yan D and Wang X: MALAT1 sponges miR-106b-5p to promote the
invasion and metastasis of colorectal cancer via SLAIN2 enhanced
microtubules mobility. EBioMedicine. 41:286–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian Y, Xu J, Li Y, Zhao R, Du S, Lv C, Wu
W, Liu R, Sheng X, Song Y, et al: MicroRNA-31 reduces inflammatory
signaling and promotes regeneration in colon epithelium, and
delivery of mimics in microspheres reduces colitis in mice.
Gastroenterology. 156:2281–2296.e2286. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Munakata K, Koi M, Kitajima T,
Tseng-Rogenski S, Uemura M, Matsuno H, Kawai K, Sekido Y, Mizushima
T, Toiyama Y, et al: Inflammation-associated microsatellite
alterations caused by MSH3 dysfunction are prevalent in ulcerative
colitis and increase with neoplastic advancement. Clin Transl
Gastroenterol. 10:e001052019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kvorjak M, Ahmed Y, Miller ML, Sriram R,
Coronnello C, Hashash JG, Hartman DJ, Telmer CA, Miskov-Zivanov N,
Finn OJ and Cascio S: Cross-talk between colon cells and
macrophages increases ST6GALNAC1 and MUC1-sTn expression in
ulcerative colitis and colitis-associated colon cancer. Cancer
Immunol Res. 8:167–178. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Min M, Peng L, Yang Y, Guo M, Wang W and
Sun G: MicroRNA-155 is involved in the pathogenesis of ulcerative
colitis by targeting FOXO3a. Inflamm Bowel Dis. 20:652–659. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin J, Welker NC, Zhao Z, Li Y, Zhang J,
Reuss SA, Zhang X, Lee H, Liu Y and Bronner MP: Novel specific
microRNA biomarkers in idiopathic inflammatory bowel disease
unrelated to disease activity. Mod Pathol. 27:602–608. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang CJ, Stratmann J, Zhou ZG and Sun XF:
Suppression of microRNA-31 increases sensitivity to 5-FU at an
early stage, and affects cell migration and invasion in HCT-116
colon cancer cells. BMC Cancer. 10:6162010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakagawa Y, Kuranaga Y, Tahara T,
Yamashita H, Shibata T, Nagasaka M, Funasaka K, Ohmiya N and Akao
Y: Induced miR-31 by 5-fluorouracil exposure contributes to the
resistance in colorectal tumors. Cancer Sci. 110:2540–2548. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cui Q: Significance of miR-27a and miR-31
in early diagnosis and prognosis of colorectal cancer. Oncol Lett.
18:3092–3096. 2019.PubMed/NCBI
|
|
30
|
Suk FM, Chang CC, Lin RJ, Lin SY, Chen YT
and Liang YC: MCPIP3 as a potential metastasis suppressor gene in
human colorectal cancer. Int J Mol Sci. 19:13502018. View Article : Google Scholar
|
|
31
|
Gong B, Liu WW, Nie WJ, Li DF, Xie ZJ, Liu
C, Liu YH, Mei P and Li ZJ: MiR-21/RASA1 axis affects malignancy of
colon cancer cells via RAS pathways. World J Gastroenterol.
21:1488–1497. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Naik R and Galande S: SATB family
chromatin organizers as master regulators of tumor progression.
Oncogene. 38:1989–2004. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Groisman G, Cai Z, Sabo E and Harpaz N:
SATB2 and Hep Par 1 immunohistochemistry is helpful in
distinguishing between inflamed and architecturally altered Ileal
pouch and rectal cuff mucosa. Int J Surg Pathol. 27:159–165. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang S, Zhou J, Wang XY, Hao JM, Chen JZ,
Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al: Down-regulated
expression of SATB2 is associated with metastasis and poor
prognosis in colorectal cancer. J Pathol. 219:114–122. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Seong BKA, Lau J, Adderley T, Kee L,
Chaukos D, Pienkowska M, Malkin D, Thorner P and Irwin MS: SATB2
enhances migration and invasion in osteosarcoma by regulating genes
involved in cytoskeletal organization. Oncogene. 34:3582–3592.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu TR, Xu LH, Yang AK, Zhong Q, Song M,
Li MZ, Hu LJ, Chen FJ, Hu ZD, Han P and Zeng MS: Decreased
expression of SATB2: A novel independent prognostic marker of worse
outcome in laryngeal carcinoma patients. PLoS One. 7:e407042012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma C, Olevian D, Miller C, Herbst C,
Jayachandran P, Kozak MM, Chang DT and Pai RK: SATB2 and CDX2 are
prognostic biomarkers in DNA mismatch repair protein deficient
colon cancer. Mod Pathol. 32:1217–1231. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin F, Shi J, Zhu S, Chen Z, Li A, Chen T,
Wang HL and Liu H: Cadherin-17 and SATB2 are sensitive and specific
immunomarkers for medullary carcinoma of the large intestine. Arch
Pathol Lab Med. 138:1015–1026. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Magnusson K, de Wit M, Brennan DJ, Johnson
LB, McGee SF, Lundberg E, Naicker K, Klinger R, Kampf C, Asplund A,
et al: SATB2 in combination with cytokeratin 20 identifies over 95%
of all colorectal carcinomas. Am J Surg Pathol. 35:937–948. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang MH, Yu J, Jiang DM, Li WL, Wang S and
Ding YQ: microRNA-182 targets special AT-rich sequence-binding
protein 2 to promote colorectal cancer proliferation and
metastasis. J Transl Med. 12:1092014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Eberhard J, Gaber A, Wangefjord S, Nodin
B, Uhlén M, Ericson Lindquist K and Jirström K: A cohort study of
the prognostic and treatment predictive value of SATB2 expression
in colorectal cancer. Br J Cancer. 106:931–938. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ma C, Henn P, Miller C, Herbst C, Hartman
DJ and Pai RK: Loss of SATB2 expression is a biomarker of
inflammatory bowel disease-associated colorectal dysplasia and
adenocarcinoma. Am J Surg Pathol. 43:1314–1322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang MH, Yu J, Chen N, Wang XY, Liu XY,
Wang S and Ding YQ: Elevated microRNA-31 expression regulates
colorectal cancer progression by repressing its target gene SATB2.
PLoS One. 8:e853532013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang YQ, Jiang DM, Hu SS, Zhao L, Wang L,
Yang MH, Ai ML, Jiang HJ, Han Y, Ding YQ and Wang S: SATB2-AS1
suppresses colorectal carcinoma aggressiveness by inhibiting
SATB2-dependent snail transcription and epithelial-mesenchymal
transition. Cancer Res. 79:3542–3556. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mir R, Pradhan SJ, Patil P, Mulherkar R
and Galande S: Wnt/β-catenin signaling regulated SATB1 promotes
colorectal cancer tumorigenesis and progression. Oncogene.
35:1679–1691. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Agrelo R, Kishimoto H, Novatchkova M,
Peraza V, Paolino M, Souabni A and Wutz A: SATB1 collaborates with
loss of p16 in cellular transformation. Oncogene. 32:5492–5500.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wan F, Cheng C, Wang Z, Xiao X, Zeng H,
Xing S, Chen X, Wang J, Li S, Zhang Y, et al: SATB1 overexpression
regulates the development and progression in bladder cancer through
EMT. PLoS One. 10:e01175182015. View Article : Google Scholar : PubMed/NCBI
|
